| CAS NO: | 182316-44-5 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 182316-44-5 |
| 别名 | 1,5,9-三氮杂环十二烷,3-亚甲基-1,5-双[(4-甲基苯基)磺酰基]-9-(苯基甲基)-,CADA |
| 分子式 | C31H39N3O4S2 |
| 分子量 | 581.79 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way[1][2]. Cyclotriazadisulfonamide (CADA) significantly decreases the amount of cell surface CD4 -the main receptor for HIV -without altering the expression of any other cellular receptor examined so far[1].Cyclotriazadisulfonamide (CADA) exhibits an EC50 of 0.4 μg/mL for CD4 in MO-DC cells. Treatment of MO-DC with 10 μg/mL of CADA results in 83% downregulation of cell surface CD4, an effect that is similar to that observed for CADA treatment of CD4+ T cells[1].CADA prevents MT-4 cells from HIV-1 and SIV infection (EC50 are 0.7 and 1.2 g/ml, respectively)[1]. [1]. Kurt Vermeire, et al. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr HIV Res. 2008 May;6(3):246-56. |
m.cnreagent.com